Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BMS-986165 in moderate to severe ulcerative colitis
NL-OMON51968Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in autoimmune colitis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Clinical response at Week 12. Started Jun 2021; status: completed.
02
Drugs
deucravacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON51968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51968.